Table 3 The urease inhibitory activities of 6a–o in the term of IC50 (µg/mL) ± SD against urease-positive microorganisms.

From: [1,2,4]triazolo[3,4-b][1,3,4]thiadiazole derivatives as new therapeutic candidates against urease positive microorganisms: design, synthesis, pharmacological evaluations, and in silico studies

Compound

C. neoformans

P. mirabilis

6a

123.7 ± 9.5

78.2 ± 8.5

6b

111.1 ± 7.4

87.3 ± 4.9

6c

117.4 ± 6.4

79.8 ± 3.5

6d

117.8 ± 8.6

91.0 ± 6.4

6e

101.9 ± 3.3

93.3 ± 5.2

6f

87.5 ± 8.1

73.2 ± 5.5

6g

94.3 ± 5.9

75.4 ± 6.1

6h

83.7 ± 3.2

74.5 ± 4.7

6i

112.2 ± 6.7

109.4 ± 6.2

6j

111.4 ± 4.8

112.3 ± 6.9

6k

118.7 ± 5.5

113.7 ± 4.6

6l

113.6 ± 5.4

91.8 ± 7.0

6m

110.9 ± 3.8

95.7 ± 6.6

6n

112.3 ± 4.6

96.8 ± 4.7

  1. Values represent means ± SD of 3 independent experiments.
Back to article page